IDEAYA Biosciences Grants Stock Options to New Hires

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /CourierPR/ -- IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has taken a significant step to bolster its team by offering inducement stock options to three newly hired employees. On September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the company's common stock. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4), which permits the granting of equity awards to individuals who were not previously employees of the company, as an inducement to their employment.

The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan, a specific plan designed for such inducements. The options have an exercise price of $36.74 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining 75% of the options will vest in equal monthly installments over the three years thereafter. Vesting is contingent upon the employees' continued service with IDEAYA.

IDEAYA Biosciences, a company dedicated to the discovery, development, and commercialization of transformative therapies for cancer, has built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs). The company's approach integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers. This strategic move reflects the company's commitment to developing tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.

The inducement grants to the new hires are part of IDEAYA's ongoing efforts to attract top talent to support its mission and drive its growth. By offering these inducement stock options, the company aims to incentivize the new employees to contribute to the advancement of its pipeline of innovative cancer therapies. The new hires join IDEAYA Biosciences at a critical time, as the company continues to expand its research and development efforts.

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4). This plan underscores IDEAYA's commitment to fostering a competitive and innovative environment, where top talent is motivated to drive the company's mission forward.

In summary, IDEAYA Biosciences has taken a strategic step to enhance its team by offering inducement stock options to three new hires, aligning with Nasdaq Listing Rule 5635(c)(4). This move reflects the company's commitment to attracting and retaining top talent to support its mission of developing personalized, effective therapies for cancer.